CCCC (C4 Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

CCCC (C4 Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

CCCCC4 Therapeutics, Inc.

Mkt Cap$243M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$36M

Net Income (TTM)-$105M

EPS (TTM)-$1.36

Free Cash Flow (TTM)-$99M

Gross Margin95.0%

Op. Margin-290.7%

Net Margin-292.1%

FCF Margin-276.2%

P/S Ratio (TTM)6.8x

P/E Ratio (TTM)—

YoY Rev Growth+1.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$4M	-$25M	-$36M
Q2 23	$3M	$3M	-$38M
Q3 23	$11M	$9M	-$28M
Q4 23	$3M	$2M	-$37M
Q1 24	$3M	$3M	-$32M
Q2 24	$12M	$10M	-$21M
Q3 24	$15M	$13M	-$28M
Q4 24	$5M	$3M	-$38M
Q1 25	$7M	$7M	-$29M
Q2 25	$6M	$6M	-$29M
Q3 25	$11M	$11M	-$34M
Q4 25	$11M	$9M	-$12M

Valuation

Quarter	P/S	P/E
Q1 23	8.9x	—
Q2 23	15.1x	—
Q3 23	11.9x	—
Q4 23	11.7x	—
Q1 24	12.1x	—
Q2 24	8.3x	—
Q3 24	7.2x	—
Q4 24	6.8x	—
Q1 25	6.1x	—
Q2 25	7.1x	—
Q3 25	8.1x	—
Q4 25	6.8x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$33M	-$34M
Q2 23	-$19M	-$19M
Q3 23	-$31M	-$31M
Q4 23	-$24M	-$24M
Q1 24	-$18M	-$18M
Q2 24	-$5M	-$5M
Q3 24	-$24M	-$24M
Q4 24	-$18M	-$18M
Q1 25	-$33M	-$33M
Q2 25	-$12M	-$12M
Q3 25	-$31M	-$32M
Q4 25	-$22M	-$22M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$589K
Q2 23	$362K
Q3 23	$600K
Q4 23	$157K
Q1 24	$0
Q2 24	$197K
Q3 24	$13K
Q4 24	$4K
Q1 25	$0
Q2 25	$185K
Q3 25	$411K
Q4 25	$11K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-50.9%	+2.5%
Q2 23	-80.7%	-2.4%
Q3 23	+63.9%	-0.9%
Q4 23	+14.3%	-1.1%
Q1 24	-19.2%	-11.8%
Q2 24	+350.7%	-16.9%
Q3 24	+38.7%	+12.2%
Q4 24	+58.8%	+5.4%
Q1 25	+138.2%	+3.2%
Q2 25	-46.2%	+4.5%
Q3 25	-26.9%	+4.7%
Q4 25	+112.8%	-45.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$6M	166.3%
Q2 23	$6M	241.2%
Q3 23	$8M	74.1%
Q4 23	$6M	195.0%
Q1 24	$6M	204.5%
Q2 24	$6M	53.1%
Q3 24	$9M	57.5%
Q4 24	$8M	159.1%
Q1 25	$6M	76.1%
Q2 25	$0	0.0%
Q3 25	$5M	40.9%
Q4 25	$4M	36.4%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$29M	$11M
Q2 23	$30M	$10M
Q3 23	$28M	$11M
Q4 23	$30M	$10M
Q1 24	$23M	$10M
Q2 24	$24M	$10M
Q3 24	$32M	$12M
Q4 24	$33M	$10M
Q1 25	$27M	$9M
Q2 25	$26M	$9M
Q3 25	$26M	$9M
Q4 25	$25M	$9M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$49M	$221M	$270M
Q2 23	$45M	$222M	$267M
Q3 23	$61M	$156M	$217M
Q4 23	$127M	$127M	$254M
Q1 24	$90M	$169M	$258M
Q2 24	$73M	$191M	$264M
Q3 24	$60M	$196M	$256M
Q4 24	$55M	$189M	$245M
Q1 25	$51M	$164M	$215M
Q2 25	$78M	$136M	$215M
Q3 25	$59M	$133M	$192M
Q4 25	$75M	$174M	$249M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	49M	+0.1%
Q2 23	49M	+0.1%
Q3 23	49M	+0.3%
Q4 23	51M	+4.1%
Q1 24	68M	+33.6%
Q2 24	69M	+0.6%
Q3 24	70M	+1.2%
Q4 24	71M	+1.4%
Q1 25	71M	+0.3%
Q2 25	71M	+0.2%
Q3 25	73M	+2.2%
Q4 25	83M	+14.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$335K	99
FY 21	$378K	121
FY 22	$213K	146
FY 23	$143K	145
FY 24	$323K	110
FY 25	$180	200K